Unlocking the Potential of FGF21: A Promising Approach to Targeting Pulmonary Fibrosis [0.03%]
FGF21潜力初探——治疗肺纤维化的可能方向
Isaac Kirubakaran Sundar
Isaac Kirubakaran Sundar
Plasma Proteomic Biomarkers Underlying Polygenic Risk of Idiopathic Pulmonary Fibrosis [0.03%]
特发性肺纤维化多基因风险的血浆蛋白质组生物标志物
Jiahao Zhu,Dan Zhou,Yu Chen et al.
Jiahao Zhu et al.
EBUS-DSA Hybrid Guidance for Complex Pulmonary Artery Stenosis Stenting in Fibrosing Mediastinitis [0.03%]
EBUS-DSA联合引导技术在纤维化纵隔炎复杂肺动脉狭窄支架植入中的应用
Yishi Li,Bin Liu,Mingjin Yang et al.
Yishi Li et al.
Is Measurement of Inspiratory Effort and Respiratory Mechanics Before Ventilator Weaning a Step Towards Personalized Medicine? [0.03%]
潮气量前测定吸气努力和呼吸力学是个性化医疗的一步吗？
Arnaud W Thille,Anaëlle Bichon,Nicolas Terzi
Arnaud W Thille
Jae Yong Oh,Myeong Ja Chung,Kum Ju Chae et al.
Jae Yong Oh et al.
Postpneumonectomy Syndrome with Mediastinal Repositioning Using Three Breast Implants [0.03%]
使用三个乳房假体进行纵隔复位的肺叶切除术后综合征
Ko-Yun Chang,John D Mitchell,Charles L Daley
Ko-Yun Chang
Reply to Zhou et al.: Refining the Utility of fSADTLC: Toward Generalizability, Cost-Effectiveness, and Longitudinal Insight [0.03%]
对周等人的回复：关于fSADTLC的效用修正：迈向可推广性、成本效益和纵向洞察力
Muhammad F A Chaudhary,Hira A Awan,Joseph M Reinhardt
Muhammad F A Chaudhary